Literature DB >> 27984714

IL-17 Blockade in Psoriasis.

Patrick R Burkett1, Vijay K Kuchroo2.   

Abstract

IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27984714     DOI： 10.1016/j.cell.2016.11.044

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  24 in total

Review 1.  Targeting IL-17 in psoriatic arthritis.

Authors:  Elizabeth A Wang; Erika Suzuki; Emanual Maverakis; Iannis E Adamopoulos
Journal:  Eur J Rheumatol       Date:  2017-11-10

Review 2.  Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review.

Authors:  Massimo Cugno; Roberta Gualtierotti; Pier Luigi Meroni; Angelo Valerio Marzano
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 3.  Improved mouse models and advanced genetic and genomic technologies for the study of neutrophils.

Authors:  Vishnu Hosur; Daniel A Skelly; Christopher Francis; Benjamin E Low; Vivek Kohar; Lisa M Burzenski; Mansoor M Amiji; Leonard D Shultz; Michael V Wiles
Journal:  Drug Discov Today       Date:  2020-05-05       Impact factor: 7.851

Review 4.  A Comprehensive Review of Neutrophilic Diseases.

Authors:  Angelo V Marzano; Alessandro Borghi; Daniel Wallach; Massimo Cugno
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

5.  Structural studies unravel the active conformation of apo RORγt nuclear receptor and a common inverse agonism of two diverse classes of RORγt inhibitors.

Authors:  Xiang Li; Marie Anderson; Delphine Collin; Ingo Muegge; John Wan; Debra Brennan; Stanley Kugler; Donna Terenzio; Charles Kennedy; Siqi Lin; Mark E Labadia; Brian Cook; Robert Hughes; Neil A Farrow
Journal:  J Biol Chem       Date:  2017-05-25       Impact factor: 5.157

Review 6.  A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.

Authors:  Yifan Hu; Zeyu Chen; Yu Gong; Yuling Shi
Journal:  Clin Drug Investig       Date:  2018-03       Impact factor: 2.859

7.  Structure-Activity Relationship Studies of Trisubstituted Isoxazoles as Selective Allosteric Ligands for the Retinoic-Acid-Receptor-Related Orphan Receptor γt.

Authors:  Femke A Meijer; Annet O W M Saris; Richard G Doveston; Guido J M Oerlemans; Rens M J M de Vries; Bente A Somsen; Anke Unger; Bert Klebl; Christian Ottmann; Peter J Cossar; Luc Brunsveld
Journal:  J Med Chem       Date:  2021-05-19       Impact factor: 7.446

Review 8.  Th17 in Animal Models of Rheumatoid Arthritis.

Authors:  Motomu Hashimoto
Journal:  J Clin Med       Date:  2017-07-21       Impact factor: 4.241

Review 9.  Autoantibodies to Chemokines and Cytokines Participate in the Regulation of Cancer and Autoimmunity.

Authors:  Nathan Karin
Journal:  Front Immunol       Date:  2018-03-29       Impact factor: 7.561

Review 10.  Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.

Authors:  Eunhye Ji; Sahmin Lee
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.